top of page

Technology
More

Use tab to navigate through the menu items.

Pipeline
More

Use tab to navigate through the menu items.

Publications
More

Use tab to navigate through the menu items.

Careers
More

Use tab to navigate through the menu items.

The Team
More

Use tab to navigate through the menu items.

Contact
More

Use tab to navigate through the menu items.

NEOVAC'S NEWS

NeoVac Announces Dr. Jan Hendrik Egberts as Chief Executive Officer

PUBLICATIONS

Lipid Nanoparticle RBD-hFc mRNA Vaccine Protects hACE2
Transgenic Mice against a Lethal SARS-CoV‑2 Infection

Design of SARS CoV 2 hFc Conjugated Receptor Binding Domain mRNA Vaccine Delivered via Lipid Nanoparticles

CRISPR-Cas9 genome editing using targeted lipid
nanoparticles for cancer therapy

Cell specific delivery of modified mRNA expressing
therapeutic proteins to leukocytes

Conformation-sensitive targeting of lipid
nanoparticles for RNA therapeutics

A Combinatorial Library of Lipid Nanoparticles for RNA
Delivery to Leukocytes

An ovarian spheroid based tumor model that
represents vascularized tumors and enables the
investigation of nanomedicine therapeutics†

A single-dose F1-based mRNA-LNP vaccine provides
protection against the lethal plague bacterium

Principles for designing an optimal mRNA lipid
nanoparticle vaccine

Lipid nanoparticles-loaded with toxin mRNA represents
a new strategy for the treatment of solid tumors

Therapeutic gene silencing of CKAP5 leads to lethality in
genetically unstable cancer cells

A Combinatorial Library of Lipid Nanoparticles for Cell
Type-Specific mRNA Delivery

Genome editing in cancer: Challenges and potential opportunities

Targeting cancer with mRNA–lipid
nanoparticles: key considerations
and future prospects

Endosomal escape: A bottleneck for LNP-mediated
therapeutics

The immunostimulatory nature of mRNA lipid nanoparticles

NeoVac Appoints Dr Heinrich Haas as
Chief Technology Officer

The future of genetic medicines delivered via targeted lipid nanoparticles
to leukocytes

Ionizable Lipids with Optimized Linkers
Enable Lung-Specific, Lipid Nanoparticle-
Mediated mRNA Delivery for Treatment of
Metastatic Lung Tumors

Lipid Nanoparticles With Fine-Tuned Composition Show
Enhanced Colon Targeting as a Platform for mRNA
Therapeutics

CONTACT US

bottom of page